Hitoo Iwase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hitoo Iwase has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Yutaka Kobayashi
Department of Internal Medicine
7 shared publicationsYoshiyuki Hiki
Division of Nephrology, Department of Internal Medicine, Fujita Health University, School of Medicine, Toyoake, Japan
6 shared publicationsIkuko Ishii-Karakasa
5 shared publicationsTakashi Sano
Department of Internal Medicine
5 shared publicationsY Hiki
Department of Internal Medicine, Nagoya University, Daiko Medical Center, Japan
5 shared publicationsTohru Kokubo
Department of Internal Medicine
4 shared publications
Latest Publications
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e11508
Clinical significance of anti-p53 antibody in the sera in patients with breast cancer.
E11508 Background: Elevation levels of anti-p53 antibody in the sera can reflects intratumoral accumulation of p53 protein and p53 gene mutation. The aim of this study is to clarify the prevalence of serum anti-p53 antibody in patients with breast cancer and to assess its clinical significance in breast cancer. Methods: We examined serum anti-p53 antibody levels in 79 patients with ductal carcinoma in situ (DCIS), 384 patients with primary invasive breast cancer without distant metastasis (PIBC) and 59 patients with distant metastatic breast cancer (MBC), using an ELISA kit. We also studied the correlation between circulating levels of anti-p53 antibody and clinicopathological factors. Results: Median levels of anti-p53 is 0.40 U/ml (range; 0 – 4.3) in 205 healthy controls. Cut-off levels of anti-p53 were previously defined 1.3 U/ml. The elevated levels of anti-p53 were detected in 10 (12.6%) of 79 patients with DCIS, 63 (16.4%) of 384 patients with PIBC, 16 (27.1%) of 59 patients with MBC. Increased levels of anti-p53 were correlated with premenopausal patients (p=0.0003) and triple negative subtype (p=0.0364). Detection rates of breast cancer using CA15-3, CEA and anti-p53 antibody were 9.3%, 20.1% and 17.1%. Serum levels of anti-p53 antibody were not correlated those of CA15-3 and CEA although serum levels of CA15-3 is significantly correlated with those of CEA (p=0.0001). Conclusions: These findings suggest serum anti-p53 antibody may detect breast cancer not detected by CA15-3 and CEA such as triple negative subtype.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e11508
Clinical significance of anti-p53 antibody in the sera in patients with breast cancer.
E11508 Background: Elevation levels of anti-p53 antibody in the sera can reflects intratumoral accumulation of p53 protein and p53 gene mutation. The aim of this study is to clarify the prevalence of serum anti-p53 antibody in patients with breast cancer and to assess its clinical significance in breast cancer. Methods: We examined serum anti-p53 antibody levels in 79 patients with ductal carcinoma in situ (DCIS), 384 patients with primary invasive breast cancer without distant metastasis (PIBC) and 59 patients with distant metastatic breast cancer (MBC), using an ELISA kit. We also studied the correlation between circulating levels of anti-p53 antibody and clinicopathological factors. Results: Median levels of anti-p53 is 0.40 U/ml (range; 0 – 4.3) in 205 healthy controls. Cut-off levels of anti-p53 were previously defined 1.3 U/ml. The elevated levels of anti-p53 were detected in 10 (12.6%) of 79 patients with DCIS, 63 (16.4%) of 384 patients with PIBC, 16 (27.1%) of 59 patients with MBC. Increased levels of anti-p53 were correlated with premenopausal patients (p=0.0003) and triple negative subtype (p=0.0364). Detection rates of breast cancer using CA15-3, CEA and anti-p53 antibody were 9.3%, 20.1% and 17.1%. Serum levels of anti-p53 antibody were not correlated those of CA15-3 and CEA although serum levels of CA15-3 is significantly correlated with those of CEA (p=0.0001). Conclusions: These findings suggest serum anti-p53 antibody may detect breast cancer not detected by CA15-3 and CEA such as triple negative subtype.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 22184
Basal cell-like signature is an independent prognostic factor in triple-negative breast cancer
22184 Background: Triple-negative (TN) breast cancer, ER(−), PgR(−) and HER2(−) subtype, has poor prognosis. TN cancer consisted of two subtypes, with or without basal-cell like signature (BC). The aim of this study is to clarify clinical and biological characteristics of TN cancer with or without BC. Methods: We examined, by IHC analysis, expression of CK5/6 and EGFR in TN breast cancer. BC was defined as CK5/6 positive and/or EGFR positive, and non-BC was defined as no expression of those two factors. We studied the correlation between the presence of basal-cell like signature and several factors related to tumor progression. We also studied the prognostic value of BC and other biological markers in TN cancer. Results: In the 39 cases of operable TN breast cancer examined, BC was detected in 15 (38.5%) cases and non-BC was detected in 24 (61.5%) cases. BC marginally correlated with nodal status (p=0.0568). BLF was also marginally associated with increased microvessel density (p=0.050) and hypoxia-inducible factor-1α (p=0.074). No association was detected BC and other biological markers. Patients who had BC in TN cancer showed shorter disease-free survival (p=0.001) and overall survival (p=0.0106) than those lacking BC. BC was an independent prognostic factor in TN cancer (Cox regression, p=0.0361) Conclusions: These findings suggest that TN cancer was divided two types of cancer from a prognostic value. It is necessary to development of novel treatment strategy for TN cancer with basal-cell like signature. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 22184
Basal cell-like signature is an independent prognostic factor in triple-negative breast cancer
22184 Background: Triple-negative (TN) breast cancer, ER(−), PgR(−) and HER2(−) subtype, has poor prognosis. TN cancer consisted of two subtypes, with or without basal-cell like signature (BC). The aim of this study is to clarify clinical and biological characteristics of TN cancer with or without BC. Methods: We examined, by IHC analysis, expression of CK5/6 and EGFR in TN breast cancer. BC was defined as CK5/6 positive and/or EGFR positive, and non-BC was defined as no expression of those two factors. We studied the correlation between the presence of basal-cell like signature and several factors related to tumor progression. We also studied the prognostic value of BC and other biological markers in TN cancer. Results: In the 39 cases of operable TN breast cancer examined, BC was detected in 15 (38.5%) cases and non-BC was detected in 24 (61.5%) cases. BC marginally correlated with nodal status (p=0.0568). BLF was also marginally associated with increased microvessel density (p=0.050) and hypoxia-inducible factor-1α (p=0.074). No association was detected BC and other biological markers. Patients who had BC in TN cancer showed shorter disease-free survival (p=0.001) and overall survival (p=0.0106) than those lacking BC. BC was an independent prognostic factor in TN cancer (Cox regression, p=0.0361) Conclusions: These findings suggest that TN cancer was divided two types of cancer from a prognostic value. It is necessary to development of novel treatment strategy for TN cancer with basal-cell like signature. No significant financial relationships to disclose.
- 2 February 2004
- Published by Wiley in Nephrology
- Vol. 9 (1) , 26-30
Detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients by using synthetic hinge peptide and glycopeptide probes*
SUMMARY: Background and Aims: There are many reports on the presence of an incompletely glycosylated O‐linked oligosaccharide(s) on the IgA1 hinge region in some immunoglobulin (IgA) nephropathy patients. Furthermore, the production of an antibody against the naked hinge peptide portion was reported in an IgA nephropathy patient. In this report, characterization of the IgG antibody against the hinge portion was carried out by using synthetic hinge glycopeptide probes.Methods and Results: The following synthetic hinge peptide and glycopeptides were prepared: 19mer peptide, V‐P‐S‐T‐P‐P‐T‐P‐S‐P‐S‐T‐P‐P‐T‐P‐S‐P‐S (designated HP), the peptide having a single α‐linked GalNAc residue at positions 4, 7, 9, 11 and 15 (4 GN − 15 GN, respectively) and the same peptide having five GalNAc residues at all five positions (GN5). The mean value of the antibody activity against these probes was compared with each other. The highest activity against the naked hinge peptide (HP) and lowest activity against the fully glycosylated hinge peptide (GN5) were obvious. As attachment of GalNAc to position 4 or 11 on the peptide brought about a significant reduction of the activity against the naked hinge peptide, the P‐S‐T‐P sequence included in both positions was thought to be the most probable site recognized by these antibodies. As an additional unexpected observation, a gender difference in this antibody activity against all the probes was found. The antibody activity in a female was significantly higher compared with that in a male.Conclusion: Because the frequency of incidence of IgA nephropathy is known to be slightly higher in males, this gender difference might indicate a protective meaning to remove aberrantly glycosylated molecules from the patient's serum.
- 2 February 2004
- Published by Wiley in Nephrology
- Vol. 9 (1) , 26-30
Detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients by using synthetic hinge peptide and glycopeptide probes*
SUMMARY: Background and Aims: There are many reports on the presence of an incompletely glycosylated O‐linked oligosaccharide(s) on the IgA1 hinge region in some immunoglobulin (IgA) nephropathy patients. Furthermore, the production of an antibody against the naked hinge peptide portion was reported in an IgA nephropathy patient. In this report, characterization of the IgG antibody against the hinge portion was carried out by using synthetic hinge glycopeptide probes.Methods and Results: The following synthetic hinge peptide and glycopeptides were prepared: 19mer peptide, V‐P‐S‐T‐P‐P‐T‐P‐S‐P‐S‐T‐P‐P‐T‐P‐S‐P‐S (designated HP), the peptide having a single α‐linked GalNAc residue at positions 4, 7, 9, 11 and 15 (4 GN − 15 GN, respectively) and the same peptide having five GalNAc residues at all five positions (GN5). The mean value of the antibody activity against these probes was compared with each other. The highest activity against the naked hinge peptide (HP) and lowest activity against the fully glycosylated hinge peptide (GN5) were obvious. As attachment of GalNAc to position 4 or 11 on the peptide brought about a significant reduction of the activity against the naked hinge peptide, the P‐S‐T‐P sequence included in both positions was thought to be the most probable site recognized by these antibodies. As an additional unexpected observation, a gender difference in this antibody activity against all the probes was found. The antibody activity in a female was significantly higher compared with that in a male.Conclusion: Because the frequency of incidence of IgA nephropathy is known to be slightly higher in males, this gender difference might indicate a protective meaning to remove aberrantly glycosylated molecules from the patient's serum.
- Open Access
- 1 June 2003
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 18 (6) , 1108-1114
Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients
Background. There are many reports of incompletely glycosylated O‐linked oligosaccharides on the IgA1 hinge region in certain IgA nephropathy patients. In addition, other reports have noted a relationship between tonsillectomy and IgA nephropathy. Methods. Immunoglobulins from extracts of tonsillectomized tissue and other sources were analysed by isoelectric focusing (IEF) and by enzyme‐linked immunosorbent assay (ELISA). Results. The IEF profile of tonsillar IgA differed from that of serum IgA and it was enriched in cationic IgA. However, extracts from tonsillitis controls and IgA nephropathy patients exhibited profiles that were very similar. Enzymatic removal of sialic acid induced a shift of the peaks to the cathode side. The profiles of IgA from treated tonsillar extract and treated serum were closely overlapped. In addition, asialo Galβ1,3GalNAc was clearly present in cationic IgA from tonsillar extract and in aberrant IgA1 from serum following enzymatic transfer of sialic acid to IgA1. Serum IgA also contained partly sialylated IgA1. Quantitative analysis of IgA and IgG in the extracts indicated that IgA was significantly higher, whereas IgG was significantly lower in IgA nephropathy patients. Conclusions. We found that the IgA1 produced in tonsillar tissue differed from serum IgA1. Furthermore, an overproduction of asialo IgA1 resulted from the disordered balance between IgA‐ and IgG‐producing cells in the tonsils from the IgA nephropathy patient. Although it is unclear how such asialo IgA1 molecules are transferred from tonsil tissue to serum, a tonsillar source may produce a few micrograms of aberrant IgA1 that then appears in serum.
- 1 June 2003
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 18 (6) , 1108-1114
Open AccessTonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients
Background. There are many reports of incompletely glycosylated O‐linked oligosaccharides on the IgA1 hinge region in certain IgA nephropathy patients. In addition, other reports have noted a relationship between tonsillectomy and IgA nephropathy. Methods. Immunoglobulins from extracts of tonsillectomized tissue and other sources were analysed by isoelectric focusing (IEF) and by enzyme‐linked immunosorbent assay (ELISA). Results. The IEF profile of tonsillar IgA differed from that of serum IgA and it was enriched in cationic IgA. However, extracts from tonsillitis controls and IgA nephropathy patients exhibited profiles that were very similar. Enzymatic removal of sialic acid induced a shift of the peaks to the cathode side. The profiles of IgA from treated tonsillar extract and treated serum were closely overlapped. In addition, asialo Galβ1,3GalNAc was clearly present in cationic IgA from tonsillar extract and in aberrant IgA1 from serum following enzymatic transfer of sialic acid to IgA1. Serum IgA also contained partly sialylated IgA1. Quantitative analysis of IgA and IgG in the extracts indicated that IgA was significantly higher, whereas IgG was significantly lower in IgA nephropathy patients. Conclusions. We found that the IgA1 produced in tonsillar tissue differed from serum IgA1. Furthermore, an overproduction of asialo IgA1 resulted from the disordered balance between IgA‐ and IgG‐producing cells in the tonsils from the IgA nephropathy patient. Although it is unclear how such asialo IgA1 molecules are transferred from tonsil tissue to serum, a tonsillar source may produce a few micrograms of aberrant IgA1 that then appears in serum.
- 24 December 2002
- Vol. 15 (6) , 703-8
Detection of enriched Thomsen-Friedenrich antigen on IgA1 from IgA nephropathy patients.
Human serum IgA1 has a mucin-like structure on its hinge portion which is composed of a mucin-type sugar chain and amino acid sequence rich in proline, serine and threonine. There are incompletely glycosylated O-linked oligosaccharide(s) on the IgA1 hinge region in some nephropathy patients. We made a detailed analysis of the incompleteness of the sugar chain by digesting IgA1 with various glycosidases. To verify the incompleteness of the sugar chains, the galactosamine/glucosamine ratio (O/N ratio) was introduced as a specific value for each IgA1 preparation. When IgA1 from serum was treated with alpha-N-acetylgalactosaminidase and/or neuraminidase or endo-beta-N-acetylglucosaminidase H (Endo-H), the O/N ratio did not change. However, endo-alpha-N-acetylgalactosaminidase (Endo-A) reduced the O/N ratio of IgA1 from the IgA nephropathy patient whereas before treatment, the O/N ratio had been similar in the normal control and IgA nephropathy. This result means there is a small amount of the unsubstituted and the sialylated N-acetylgalactosamine residues (Tn and sialyl Tn antigen, respectively), and abundant asialo Galbeta1,3GalNAc (TF antigen) in the IgA1 molecule. In view of the incompleteness of the IgA1 sugar chain, the decrease in the sialic acid content of the mucin-type sugar chain on IgA1 from an IgA nephropathy patient became obvious in this experiment.
- 24 December 2002
- Vol. 15 (6) , 703-8
Detection of enriched Thomsen-Friedenrich antigen on IgA1 from IgA nephropathy patients.
Human serum IgA1 has a mucin-like structure on its hinge portion which is composed of a mucin-type sugar chain and amino acid sequence rich in proline, serine and threonine. There are incompletely glycosylated O-linked oligosaccharide(s) on the IgA1 hinge region in some nephropathy patients. We made a detailed analysis of the incompleteness of the sugar chain by digesting IgA1 with various glycosidases. To verify the incompleteness of the sugar chains, the galactosamine/glucosamine ratio (O/N ratio) was introduced as a specific value for each IgA1 preparation. When IgA1 from serum was treated with alpha-N-acetylgalactosaminidase and/or neuraminidase or endo-beta-N-acetylglucosaminidase H (Endo-H), the O/N ratio did not change. However, endo-alpha-N-acetylgalactosaminidase (Endo-A) reduced the O/N ratio of IgA1 from the IgA nephropathy patient whereas before treatment, the O/N ratio had been similar in the normal control and IgA nephropathy. This result means there is a small amount of the unsubstituted and the sialylated N-acetylgalactosamine residues (Tn and sialyl Tn antigen, respectively), and abundant asialo Galbeta1,3GalNAc (TF antigen) in the IgA1 molecule. In view of the incompleteness of the IgA1 sugar chain, the decrease in the sialic acid content of the mucin-type sugar chain on IgA1 from an IgA nephropathy patient became obvious in this experiment.
- 1 August 2002
- Published by Elsevier in Journal of Chromatography B
- Vol. 776 (1) , 101-106
Quantitative analysis of IgA1 binding protein prepared from human serum by hypoglycosylated IgA1/Sepharose affinity chromatography
- 1 August 2002
- Published by Elsevier in Journal of Chromatography B
- Vol. 776 (1) , 101-106
Quantitative analysis of IgA1 binding protein prepared from human serum by hypoglycosylated IgA1/Sepharose affinity chromatography
- 1 December 2001
- Published by Wiley in Nephrology
- Vol. 6 (s1) , A25
Influence of O-glycans in IgA1 hinge on its biological activity in human mesangial cells: A comprehensive gene expression profiling analysis using cDNA array
- 1 December 2001
- Published by Wiley in Nephrology
- Vol. 6 (s1) , A25
Influence of O-glycans in IgA1 hinge on its biological activity in human mesangial cells: A comprehensive gene expression profiling analysis using cDNA array
- 1 December 2001
- Published by Wiley in Nephrology
- Vol. 6 (s1) , A7-A8
Quantitative analysis of IgA1 binding protein in human serum by hypoglycosylated IgA1/Sepharose chromatography
- 1 December 2001
- Published by Wiley in Nephrology
- Vol. 6 (s1) , A7-A8
Quantitative analysis of IgA1 binding protein in human serum by hypoglycosylated IgA1/Sepharose chromatography
- 1 January 2001
- Published by Elsevier in Analytical Biochemistry
- Vol. 288 (1) , 22-27
Analysis of the Microheterogeneity of the IgA1 Hinge Glycopeptide Having Multiple O-Linked Oligosaccharides by Capillary Electrophoresis
- 1 January 2001
- Published by Elsevier in Analytical Biochemistry
- Vol. 288 (1) , 22-27
Analysis of the Microheterogeneity of the IgA1 Hinge Glycopeptide Having Multiple O-Linked Oligosaccharides by Capillary Electrophoresis